A groundbreaking technology designed to attack lung tumors and shorten recovery times for patients is now available at St.

St Vincent's Hospital reviewed the records of more than 1,500 patients who saw cancer genetics specialist Allan Spigelman between April 2022 and June 2023. It found problems in the records of more ...

Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get the powerful ...

Alan faced the prospect of losing his bladder when he was diagnosed with bladder cancer in 2020. Now he’s in remission thanks ...

Amplia Therapeutics is making strides with its candidate that works on the anti-fibrotic path to tackling pancreatic cancer.

Emeritus Professor Allan Spigelman is at the centre of an internal review of medical records for more than 1600 patients at St Vincent’s Hospital Sydney’s cancer genetic service between April ...

Researchers are developing an in vivo approach to engineer cancer-fighting immune cells, potentially making the powerful CAR ...

The Trump administration's broadside against higher education's ideological rot should not stop at Harvard, it should only ...

Flaks, commenting on the prevalence of cancer diagnoses in Connecticut, said the new center will “dramatically accelerate” bringing innovation to Connecticut, and Hartford HealthCare hopes eventually ...

The daughter of a Bridgeport Navy veteran who died of cancer is hosting a swim-a-thon fundraiser in his honor. The proceeds ...

Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential ...

T therapies is an expensive business. The fundamental problem is that CAR-T production is not a good fit for centralized manufacturing.